NCI Radiation Oncology Branch Acquisition of Elekta Unity Linac System for Radiation Therapy
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute within the National Institutes of Health intends to award a sole-source, firm-fixed-price contract to Elekta, Inc. for the acquisition of a fully integrated 1.5 Tesla magnetic resonance-guided linear accelerator system, critical for advanced radiation therapy and clinical research. This system must include a 7 MV photon beam, a 160-leaf multileaf collimator, an onboard 1.5T or higher MRI scanner with specialized imaging protocols for radiotherapy, diffusion weighted imaging capability, motion-adaptive treatment functionality, a low-attenuation MR receive coil, a dedicated MRI console, an indexable patient positioning system, and comprehensive quality assurance software. The requirement stems from the necessity of a single integrated platform that eliminates geometric uncertainties by combining imaging and treatment in one coordinate system, which no other commercially available system currently satisfies. Sole-source justification is supported by statutory authority under 41 U.S.C. 3304(a)(1) and FAR 6.302-1, as Elekta is the only entity capable of delivering a system meeting all minimum technical specifications with full OEM installation, commissioning, training, and warranty support. Responses to this notice are not mandatory but are invited from any responsible source that believes it can meet the Government’s unique requirements. Interested parties must submit a capability statement no later than July 30, 2026, at 11:00 AM Eastern Time, limited to ten pages and including company details, UEI number, point of contact, a technical description of the proposed system, evidence of compliance with all specified characteristics, proof of OEM authorization, and relevant past performance. The Government will evaluate submissions to determine whether competition is feasible; failure to demonstrate full alignment with the minimum requirements will not result in further consideration. This notice does not constitute a solicitation, nor will the Government assume responsibility for any costs associated with response preparation. All correspondence and submissions should be directed to Linda Smith or Danielle Tines at the provided email addresses.
General Info
Agency
NAICS
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Notice of Intent to Sole Source
Notice ID: NIH-NOI-26-PCA-NCI-09516
Agency / Office: Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI)
Notice Type: Special Notice
Posted Date: July 20, 2026
Response Date: July 30, 2026, 11:00 AM Eastern Time
NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing
PSC: 6515 – Medical and Surgical Instruments, Equipment, and Supplies
Contracting Office Address:
National Institutes of Health
National Cancer Institute
Description
This is a combined synopsis / notice of intent to sole source and is not a request for competitive quotations or proposals.
The National Institutes of Health (NIH), National Cancer Institute (NCI), on behalf of the Center for Cancer Research (CCR), Radiation Oncology Branch (ROB), intends to negotiate and award a sole-source firm-fixed-price contract to Elekta, Inc., 400 Perimeter Center Terrace NE, Suite 50, Atlanta, GA 30346, for the acquisition, delivery, installation, commissioning, training, and warranty of an integrated magnetic resonance-guided linear accelerator system.
The statutory authority for this proposed sole-source action is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.
Requirement
The Government requires a fully integrated MR-guided linear accelerator system to support patient treatment and clinical research. The minimum salient characteristics include:
- 7 Megavoltage (MV) photon beam
- 160-leaf multileaf collimator (MLC)
- Onboard 1.5 Tesla (or greater) magnetic resonance imaging system
- Imaging protocols explicitly created for MR-guided external beam radiotherapy
- Capability for Diffusion Weighted Imaging (DWI)
- Capability for imaging and treating in the presence of patient motion
- MR receive coil with low attenuation of the radiation beam
- Dedicated MRI console for imaging guidance and control
- Patient positioning system including flat table, comfort mattress, and indexable table
- Quality assurance capabilities and supporting software
- Site planning, delivery, installation, commissioning, training, and warranty
This equipment is mission-critical to patient treatment and clinical research because it enables high-resolution soft-tissue visualization and adaptive radiotherapy in a single integrated coordinate system, reducing geometric uncertainty associated with moving a patient between separate imaging and treatment systems.
Sole Source Basis
Based on market research, Elekta, Inc. is the only known responsible source capable of providing a commercially available, fully integrated 1.5 Tesla MR-guided linear accelerator system meeting the Government’s minimum needs.
The Government reviewed other systems in the broader radiation oncology market, including lower-field MR-guided systems, CBCT-based adaptive radiotherapy systems, and standalone MRI platforms. These alternatives do not satisfy the Government’s minimum requirement for a fully integrated 1.5T MR-Linac with the required imaging, treatment, adaptive planning, and OEM installation capabilities.
In addition, the proprietary nature of the system and the specialized site planning, shielding, installation, and commissioning requirements make Elekta the only responsible source for both the equipment and the associated implementation services.
Response Information
This notice is for informational purposes only. Any responsible source that believes it can meet the Government’s requirement may submit a capability statement for Government consideration.
Capability statements must clearly demonstrate the vendor’s ability to provide a commercially available, fully integrated 1.5 Tesla (or greater) MR-guided linear accelerator system meeting all minimum salient characteristics, including OEM-authorized delivery, installation, commissioning, training, and warranty support.
Responses must be submitted electronically no later than 11:00 AM Eastern Time on July 30, 2026.
Responses shall be limited to 10 pages and must include:
- Company name and address
- UEI number
- Point of contact name, email address, and telephone number
- Technical description of the proposed system
- Evidence that the proposed system meets all minimum salient characteristics
- Evidence of OEM authorization for sale, installation, and support
- Relevant past performance information for similar Federal or commercial installations
The Government will review all capability statements received by the closing date. A determination by the Government not to compete this proposed action based on responses to this notice is solely within the discretion of the Government.
Primary Point of Contact
Linda Smith
linda.smith2@nih.gov
Secondary Point of Contact
Danielle Tines
danielle.tines@nih.gov
Disclaimer
This notice does not constitute a solicitation, request for proposal, or request for quotation. The Government is not responsible for any costs incurred in responding to this notice.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency